Systematic construction and external validation of an immune-related prognostic model for nasopharyngeal carcinoma.
C-index
absolute lymphocyte count
decision curve analysis
immune-related indices
nasopharyngeal carcinoma
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
18
01
2022
received:
30
09
2021
accepted:
01
02
2022
pubmed:
17
2
2022
medline:
8
4
2022
entrez:
16
2
2022
Statut:
ppublish
Résumé
We attempted to identify the most reliable immune-related index for predicting nasopharyngeal carcinoma (NPC) prognosis and to reveal its precise and integrated relationship with NPC progression. One thousand seven hundred and six patients with newly diagnosed NPC (1320 from the primary cohort and 386 from the validated cohort) from January 2010 to March 2014 were enrolled. Clinical features and 12 immune-related variables were analyzed. A high absolute lymphocyte count (ALC; >3.2 × 10 High ALC is a surrogate marker for improved prognostic risk stratification in NPC.
Sections du résumé
BACKGROUND
We attempted to identify the most reliable immune-related index for predicting nasopharyngeal carcinoma (NPC) prognosis and to reveal its precise and integrated relationship with NPC progression.
METHOD
One thousand seven hundred and six patients with newly diagnosed NPC (1320 from the primary cohort and 386 from the validated cohort) from January 2010 to March 2014 were enrolled. Clinical features and 12 immune-related variables were analyzed.
RESULTS
A high absolute lymphocyte count (ALC; >3.2 × 10
CONCLUSION
High ALC is a surrogate marker for improved prognostic risk stratification in NPC.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1086-1098Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Xia L, Xu YJ, Xu XJ, Meng RL, Lin LF. Cancer incidence and mortality in Pearl River Delta area, 2009-2013. Zhonghua Zhong Liu Za Zhi. 2019;41:393-397.
Li K, Lin GZ, Shen JC, Zhou Q. Time trends of nasopharyngeal carcinoma in urban Guangzhou over a 12-year period (2000-2011): declines in both incidence and mortality. Asian Pac J Cancer Prev. 2014;15:9899-9903.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-545.
Krant MJ, Manskopf G, Brandrup CS, Madoff MA. Immunologic alterations in bronchogenic cancer. Seq Study Cancer. 1968;21:623-631.
Forget P, Echeverria G, Giglioli S, et al. Biomarkers in immunonutrition programme, is there still a need for new ones? A brief review. Ecancermedicalscience. 2015;9:546.
Ohno Y. Role of systemic inflammatory response markers in urological malignancy. Int J Urol. 2019;26:31-47.
Pan XB, Huang ST, Zhu XD. Neutrophil-to-lymphocyte ratio predicts the prognosis of stage II nasopharyngeal carcinoma. Cancer Manag Res. 2019;11:8269-8275.
Liu LT, Liang YJ, Guo SS, et al. Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: a study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein-Barr virus DNA. Head Neck. 2022;44:34-45.
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-899.
Zhang Y, Zhou GQ, Liu X, et al. Exploration and validation of C-reactive protein/albumin ratio as a novel inflammation-based prognostic marker in nasopharyngeal carcinoma. J Cancer. 2016;7:1406-1412.
Lu A, Li H, Zheng Y, et al. Prognostic significance of neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio, and platelet to lymphocyte ratio in patients with nasopharyngeal carcinoma. Biomed Res Int. 2017;2017:3047802.
Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual. 8th ed. Springer; 2017.
Tang LQ, Li CF, Li J, et al. Establishment and validation of prognostic nomograms for endemic nasopharyngeal carcinoma. J Natl Cancer Inst. 2015;108:djv291.
Zhao C, Han F, Lu LX, et al. Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma. Ai Zheng. 2004;23:1532-1537.
Li WF, Li YQ, Chen L, et al. Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy. BMC Cancer. 2015;15:810.
Lai SZ, Li WF, Chen L, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011;80:661-668.
Zhang Z, Rousson V, Lee WC, et al. Decision curve analysis: a technical note. Ann Transl Med. 2018;6:308.
Chen YP, Chan A, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394:64-80.
Su L, Zhang M, Zhang W, Cai C, Hong J. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96:e6364.
Lin YH, Chang KP, Lin YS, Chang TS. Pretreatment combination of platelet counts and neutrophil-lymphocyte ratio predicts survival of nasopharyngeal cancer patients receiving intensity-modulated radiotherapy. Onco Targets Ther. 2017;10:2751-2760.
Tu X, Ren J, Zhao Y. Prognostic value of prognostic nutritional index in nasopharyngeal carcinoma: a meta-analysis containing 4511 patients. Oral Oncol. 2020;110:104991.
Liu LT, Chen QY, Tang LQ, et al. The prognostic value of treatment-related lymphopenia in nasopharyngeal carcinoma patients. Cancer Res Treat. 2018;50:19-29.
Li X, Han Z, Cheng Z, Yu J, Yu X, Liang P. Prognostic value of preoperative absolute lymphocyte count in recurrent hepatocellular carcinoma following thermal ablation: a retrospective analysis. Onco Targets Ther. 2014;7:1829-1835.
Huang Y, Wang F, Wang Y, et al. Intrahepatic interleukin-17+ T cells and FoxP3+ regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:851-859.
Wang M, Li C, Wen TF, Peng W, Chen LP. Postoperative low absolute lymphocyte counts may predict poor outcomes of hepatocellular carcinoma after liver resection. Chin Med J (Engl). 2016;129:536-541.
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
Wang YQ, Chen YP, Zhang Y, et al. Prognostic significance of tumor-infiltrating lymphocytes in nondisseminated nasopharyngeal carcinoma: a large-scale cohort study. Int J Cancer. 2018;142:2558-2566.
Fogar P, Sperti C, Basso D, et al. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas. 2006;32:22-28.
Menon AG, Janssen-van RC, Morreau H, et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest. 2004;84:493-501.
Guedan S, Ruella M, June CH. Emerging cellular therapies for cancer. Annu Rev Immunol. 2019;37:145-171.
Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91:181-184.